Press Releases

 Sign up for email alerts here

 

Date Title and Summary Additional Formats
Toggle Summary Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017
- ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types - - ATLAS also identifies unique tumor-associated antigen response signatures in patients with lung and colorectal cancers - CAMBRIDGE, Mass. , Nov.
View HTML
Toggle Summary Genocea Reports Third Quarter 2017 Financial Results
 - SITC presentation to highlight ATLAS™ ability in neoantigen selection -  - IND filing for neoantigen cancer vaccine, GEN-009, expected in Q1 2018 -  - Conference call today at 9 am ET - CAMBRIDGE, Mass. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
View HTML
Toggle Summary Genocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ET
CAMBRIDGE, Mass. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, November 2, 2017 at 9:00 a.m.
View HTML
Toggle Summary Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines
- Superior ATLAS TM platform for neoantigen selection (1) -  - Exploring strategic alternatives for GEN-003 - - Announces corporate restructuring - CAMBRIDGE, Mass. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company discovering and developing
View HTML
Toggle Summary Genocea to Present at Cantor Fitzgerald Healthcare Conference
CAMBRIDGE, Mass. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens,  today announced that Chip Clark , president and chief executive officer, will present a company
View HTML
Toggle Summary Genocea Biosciences Reports Second Quarter 2017 Financial Results
- Recently reported positive t op- l ine 12- month Phase 2b data for GEN-003 in genital herpes - - IND filing for neoantigen cancer vaccine, GEN-009, expected in Q4 2017 - CAMBRIDGE, Mass. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company
View HTML
Toggle Summary Genocea Biosciences to Highlight GEN-003 Clinical Data at the 42nd Annual International Herpesvirus Workshop
- Pre-Conference symposium, posters, and oral presentation will highlight GEN-003 Phase 2b clinical data - CAMBRIDGE, Mass. , July 28, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell
View HTML
Toggle Summary Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
- Statistically significant result on expected Phase 3 primary endpoint with Phase 3 dose - - Positive results on multiple secondary clinical endpoints - - Potentially the first new treatment in more than 20 years for the millions infected with genital herpes - - Conference call today at 8 a.m.
View HTML
Toggle Summary Genocea Added to Russell 3000® and Russell 2000® Indices
CAMBRIDGE, Mass. , June 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it has been added to the Russell 3000 ® and Russell 2000 ® Indices as part of the annual
View HTML
Toggle Summary Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes
- D ata from GEN-003 Phase 2 trial indicate initial course of injections  sustains clinical and virologic efficacy for at least 2 4 months - - End of Phase 2 meeting successfully completed for GEN-003 ; expect to be Phase 3-ready by end of 2017 - - Neoantigen cancer vaccine candidate GEN-009 IND
View HTML
Toggle Summary Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET
CAMBRIDGE, Mass. , April 27, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 4, 2017 at 9:00 a.m.
View HTML
Toggle Summary Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes
Company highlights its T cell-Directed Genital Herpes and Neoantigen Cancer Vaccine Candidates in two oral presentations
View HTML
Toggle Summary Genocea to Present at the 16th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. , March 29, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a company overview at the 16 th
View HTML
Toggle Summary Howard Mayer, M.D., of Shire, Joins Genocea Biosciences' Board of Directors
Dr. Mayer brings significant depth of experience in global clinical drug development
View HTML
Toggle Summary Genocea to Present at the Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass. , March 01, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole , chief financial officer, will present a company overview at the upcoming Cowen
View HTML